Keywords: actelion, tracleer, approved, eu, treatment, digital, ulcers
Actelion's Tracleer approved in EU for treatment of digital ulcers
Article | 18 June 2007
Swiss biotechnology firm Actelion says that Tracleer (bosentan), its dual endothelin receptor antagonist, has been approved in the European Union ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
